文献速递妇科

FIGO 2018分期在现代放疗时代宫颈癌中的肿瘤学结局

Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.
PubMed 文献 · Gynecol Oncol · 2021-05-29

本研究回顾性分析2010-2018年接受根治性放化疗的216例非转移性宫颈癌患者,所有患者治疗前均行MRI和CT/PET,采用调强外照射和三维图像引导近距离放疗。中位随访44.3个月,5年总生存率76.8%、无病生存率68.5%、局部区域无病生存率82.6%。FIGO 2018分期较2009版对总生存区分更好,但远处复发仍是重要问题。

要点

  • FIGO 2018分期较2009版对总生存区分更好
  • 盆腔和腹主动脉旁淋巴结阳性者总生存逐步变差(p<0.001)
  • 图像引导放疗下局部区域控制良好,但远处复发仍突出

核心结论

  • 在现代图像引导放疗时代,FIGO 2018分期能更好反映宫颈癌患者预后,但远处复发仍是重要问题,提示IIIC期需新治疗策略。

研究设计与样本

  • 单中心回顾性队列研究,纳入2010-2018年接受根治性放化疗的216例成人非转移性宫颈癌患者,所有患者治疗前均有MRI和CT/PET,治疗采用调强外照射和三维图像引导近距离放疗。

主要发现

  • 中位随访44.3个月,5年总生存率、无病生存率和局部区域无病生存率分别为76.8%、68.5%和82.6%。
  • FIGO 2018分期较2009版对总生存区分更好,盆腔和腹主动脉旁淋巴结阳性者总生存逐步变差(p<0.001)。
  • 多因素分析中,体能状态(p=0.044)和FIGO 2018分期(III期p=0.016;IVA期p=0.010)是死亡预测因素;FIGO 2018分期(III期p=0.003;IVA期p=0.001)是任何复发的预测因素;MRI肿瘤直径(p≤0.001)和淋巴结转移(p=0.024)是局部区域复发的预测因素。

临床怎么用

  • 采用FIGO 2018分期结合治疗前MRI和CT/PET进行精准分期,有助于更准确评估宫颈癌预后。
  • 对IIIC期宫颈癌应关注远处复发风险,探索新的治疗策略。

局限性

  • 单中心回顾性研究,样本量216例,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The recently published ASTRO cervical cancer guidelines recommend the use of modern radiotherapy. Imaging is now incorporated in the updated FIGO 2018 staging with a new stage IIIC. This study aims to evaluate the oncologic outcomes and predictors of survival using FIGO 2018 staging in a cohort of patients treated in an era of high-precision image-guided radiotherapy. METHODS: We performed a retrospective cohort study of 216 adult cervical cancer patients treated with definitive chemoradiotherapy between 2010 and 2018. Eligible patients had non-metastatic cervical cancer treated at a single academic institution. All patients had pre-treatment MRI and CT/PET. Treatment protocol consisted of external beam intensity-modulated radiotherapy and 3D image-guided brachytherapy. Kaplan-Meier curves were used for survival analysis. Multivariate cox proportional-hazards model was performed to identify potential prognostic factors. RESULTS: Median age at diagnosis was 50 and median BMI was 26.4 kg/m2. Median follow-up time was 44.3 months. Five-year overall survival (OS), disease-free survival and loco-regional disease-free survival rates were 76.8%, 68.5% and 82.6%, respectively. FIGO 2018 showed better OS discrimination compared to FIGO 2009 classification. OS was increasingly worse with positive pelvic and para-aortic nodes (p < 0.001). In a multivariate prediction model, performance status (p = 0.044) and FIGO 2018 classification (stage III p = 0.016; stage IVA p = 0.010) were predictors of mortality; FIGO 2018 classification (stage III p = 0.003; stage IVA p = 0.001) was a predictor of any recurrence; MRI tumor diameter (p ≤ 0.001) and nodal metastases (p = 0.024) were predictors of loco-regional recurrence. CONCLUSIONS: Integration of state-of-the-art imaging in cervical cancer staging and in radiotherapy planning leads to good loco-regional control rates, however distant recurrence remains an important issue. FIGO 2018 staging better reflects patient prognosis, highlighting the need for new treatment strategies for stage IIIC cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Brodeur MN, Dejean R, Beauchemin MC, et al. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer. Gynecol Oncol. 2021. PMID: 34059350. doi:10.1016/j.ygyno.2021.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。